Toulouse

• Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting
  2024-511879-16-00 5 2024-12-12 Prurigo Nodularis
• ISASOCUT-IFM2022-05-Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib, lenalidomide and dexamethasone in the treatment of … Recruiting
  2024-517099-39-00 4 2024-11-18 Newly diagnosed transplant ineligible multiple myeloma
• A preventive study of bleeding episodes for children with severe von Willebrand disease (VWD). Recruiting
  2023-509877-22-00 5 2024-10-30 severe von Willebrand Disease
• Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) Recruiting
  2024-513219-29-00 5 2024-10-21 Renal Cell Carcinoma
• A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Teno … Recruiting
  2023-510422-32-00 5 2024-09-10 Tenosynovial Giant Cell Tumour
• A Study to see how safe is RO7567132 as Single Agent and in Combination with Atezolizumab, how the body gets rid of it and how effective it … Recruiting
  2024-512839-70-00 1 2024-08-27 Advanced and/or Metastatic Solid Tumors
• A study of different investigational treatments in people with the interstitial lung disease that accompanies scleroderma (CONQUEST) Recruiting
  2023-507129-40-00 4 2024-08-06 interstitial lung disease secondary to systemic sclerosis (SSc-ILD)
• Beamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps … Recruiting
  2023-509566-38-00 9 2024-08-05 gastroesophageal junction adenocarcinoma
• Reperfusion with P2Y12 inhibitors in addition to mechanical thrombectomy for perfusion imaging selected acute stroke patients : a multicentr … Recruiting
  2024-516163-88-00 11 2024-08-01 Acute ischemic stroke
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis Recruiting
  2023-503699-25-00 5 2024-07-15 Progressive Pulmonary Fibrosis
• A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of Etentamig (ABBV-383) in patients with relap … Recruiting
  2023-507901-32-00 3 2024-06-28 Relapsed or Refractory Multiple Myeloma (R/R MM)
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis Recruiting
  2023-503697-21-01 5 2024-06-24 Idiopathic pulmonary fibrosis
• BEAMION Lung-2: A study to test whether zongertinib (BI 1810631) helps people with advanced non-small cell lung cancer with HER2 mutations c … Recruiting
  2023-504308-27-00 5 2024-06-06 non-squamous non-small cell lung cancer
• A Phase 1b/2 Study of JNJ-90014496 in Adult Participants with B-cell Non-Hodgkin Lymphoma Recruiting
  2023-506267-33-00 3 2024-05-29 Non-Hodgkin Lymphoid Malignancies
• A phase 2b, randomized, double-blind study of redasemtide (S-005151) in adult participants with acute ischemic stroke Recruiting
  2022-501890-38-00 4 2024-02-16 acute ischemic stroke
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E … Recruiting
  2023-505121-14-00 5 2024-01-18 Moderate to Severe Plaque Psoriasis
• A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III N … Recruiting
  2023-503920-14-00 5 2024-01-02 Non-Small Cell Lung Cancer (NSCLC)
• Long-term Extension Study to Assess Adverse Events and Tolerability of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Ag … Recruiting
  2022-501099-24-00 5 2023-12-22 Migraine
• Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alz … Recruiting
  2022-503148-41-00 4 2023-12-01 Alzheimer's disease
• A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) … Recruiting
  2022-501100-94-00 5 2023-11-08 Episodic Migraine
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• A study of efficacy and safety of ianalumab in previously treated patients with warm autoimmune haemolytic anaemia Recruiting
  2024-510635-21-00 5 2023-05-09 warm autoimmune haemolytic anaemia (wAIHA)
• (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Recruiting
  2022-501427-24-00 4 2023-04-25 Nonadvanced Systemic Mastocytosis
• A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Placebo-Controlled Phase 3 Followed by an Ope … Recruiting
  2023-509672-42-00 5 2023-02-02 GRIN-related neurodevelopmental disorder

Showing 97–120 of 642 trials